Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + vinorelbine
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Toripalimab + vinorelbine is a combination therapy consisting of toripalimab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1), and vinorelbine, a semi-synthetic vinca alkaloid chemotherapeutic agent. Toripalimab acts as an immune checkpoint inhibitor by blocking PD-1 on T cells, thereby enhancing anti-tumor immune responses. Vinorelbine disrupts microtubule formation during cell division, exerting cytotoxic effects on rapidly proliferating cancer cells. This combination has been investigated primarily in HER2-negative metastatic breast cancer—including triple-negative breast cancer—where it aims to leverage both immunotherapy and chemotherapy for improved efficacy[1][2][3].
- Other names
- toripalimab plus vinorelbinetoripalimab and vinorelbine
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on toripalimab + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + vinorelbine.